These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 38528388)

  • 1. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
    Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific controlled-release nanoparticles for immune reprogramming via dual metabolic inhibition against triple-negative breast cancer.
    She W; Li H; Wang Z; Liu T; Zhao D; Guo Z; Liu Y; Liu Y
    J Control Release; 2024 Feb; 366():204-220. PubMed ID: 38109945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Nano-Delivery Systems Remodel the Immunosuppressive Tumor Microenvironment for Metastatic Triple-Negative Breast Cancer Therapy.
    Bai L; Liu H; You R; Jiang X; Zhang T; Li Y; Shan T; Qian Z; Wang Y; Liu Y; Li C
    Mol Pharm; 2024 May; 21(5):2148-2162. PubMed ID: 38536949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance.
    Sa P; Sahoo SK; Dilnawaz F
    Curr Med Chem; 2023; 30(29):3335-3355. PubMed ID: 36154585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment.
    Roma-Rodrigues C; Raposo LR; Valente R; Fernandes AR; Baptista PV
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1704. PubMed ID: 33565269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment-regulating nanomedicine design to fight multi-drug resistant tumors.
    Xu Q; Lan X; Lin H; Xi Q; Wang M; Quan X; Yao G; Yu Z; Wang Y; Yu M
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Jan; 15(1):e1842. PubMed ID: 35989568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.
    Wu TN; Chen HM; Shyur LF
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diselenium-linked dimeric prodrug nanomedicine breaking the intracellular redox balance for triple-negative breast cancer targeted therapy.
    Chen M; Zhang M; Lu X; Li Y; Lu C
    Eur J Pharm Biopharm; 2023 Dec; 193():16-27. PubMed ID: 37865134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
    Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
    Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative Nanomaterials for Targeting Hypoxia to Improve Treatment for Triple-negative Breast Cancer.
    Ray SK; Mukherjee S
    Recent Pat Biotechnol; 2024; 18(4):269-272. PubMed ID: 37957916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
    Miller-Kleinhenz JM; Bozeman EN; Yang L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
    He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
    Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency.
    Wu Y; Chen R; Ni S; Hu K
    J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment.
    Arroyo-Crespo JJ; Armiñán A; Charbonnier D; Balzano-Nogueira L; Huertas-López F; Martí C; Tarazona S; Forteza J; Conesa A; Vicent MJ
    Biomaterials; 2018 Dec; 186():8-21. PubMed ID: 30278346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell surface-nanoengineering for cancer targeting immunoregulation and precise immunotherapy.
    Wang Y; Huang G; Hou Q; Pan H; Cai L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(4):e1875. PubMed ID: 36567668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in nanotheranostics for triple negative breast cancer treatment.
    Thakur V; Kutty RV
    J Exp Clin Cancer Res; 2019 Oct; 38(1):430. PubMed ID: 31661003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
    Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
    J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymeric nanoparticles as a promising platform for treating triple-negative breast cancer: Current status and future perspectives.
    Bazzazan MA; Fattollazadeh P; Keshavarz Shahbaz S; Rezaei N
    Int J Pharm; 2024 Oct; 664():124639. PubMed ID: 39187034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.